Review: Membrane-associated misfolded protein propagation in natural transmissible spongiform encephalopathies (TSEs), synthetic prion diseases and Alzheimer's disease

Neuropathology and Applied Neurobiology

Volumn 39, Issue 3, 2013, Pages 196-216

  Jeffrey, M ^a  

^a VETERINARY LABORATORIES AGENCY   (United Kingdom)

Author keywords

A ; Alzheimer's disease; Prion; Prion protein; Protein misfolding; Transmissible spongiform encephalopathy

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; MUTANT PROTEIN; OLIGOMER; PRION PROTEIN; RECOMBINANT PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYLOIDOSIS; CELL MEMBRANE; CHRONIC WASTING DISEASE; CHRONIC WASTING DISEASE AGENT; CLINICAL FEATURE; CREUTZFELDT JAKOB DISEASE; ELECTRON MICROSCOPY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MEMBRANE STRUCTURE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PHENOTYPE; PRION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; SCRAPIE; SCRAPIE AGENT; SYNTHETIC PRION DISEASE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; HUMANS; PRION DISEASES; PROTEOSTASIS DEFICIENCIES;

EID: 84874962928     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/nan.12004     Document Type: Review

References (104)

1. Ironside JW, Ghetti B, Head MW, Piccardo P, Will RG. Prion diseases. In Greenfield's Neuropathology. Eds S Love, DN Louis, DW Ellison . London: Hodder Arnold, 2009; 1197-1273
2. Prusiner SB. Development of the prion concept. In Prion Biology and Diseases. Ed SB Prusiner . Plainview, NY: Cold Spring Harbor Laboratory Press, 1999; 67-112
3. Jeffrey M, González L. Classical sheep transmissible spongiform encephalopathies: pathogenesis, pathological phenotypes and clinical disease. Neuropathol Appl Neurobiol 2007; 33: 373-394
4. Safar J, Wille H, Itrri V, Groth D, Serban H, Torchia M, DeArmond SJ, Prusiner SB. Eight prion strains have PrPSc molecules with different conformations. Nat Med 1998; 4: 1157-1165
5. Colby DW, Wain R, Baskakov IV, Legname G, Palmer CG, Nguyen HO, Lemus A, Cohen FE, DeArmond SJ, Prusiner SB. Protease-sensitive synthetic prions. PLoS Pathog 2010; 6: e1000736
6. Safar JG, Geschwind MD, Deering C, Didorenko S, Sattavat M, Sanchez H, Prusiner SB. Diagnosis of human prion disease. Proc Natl Acad Sci U S A 2005; 102: 3501-3506
7. Benestad SL, Arsac JN, Goldmann W, Noremark M. Atypical/Nor98 scrapie: properties of the agent, genetics, and epidemiology. Vet Res 2008; 39: 19-33
8. González L, Terry L, Jeffrey M. Expression of prion protein in the gut of mice infected orally with the 301V murine strain of the bovine spongiform encephalopathy agent. J Comp Pathol 2005; 132: 273-282
9. González L, Dagleish MP, Martin S, Finlayson J, Siso S, Eaton SL, Goldmann W, Witz J, Hamilton S, Stewart P, Pang Y, Steele P, Reid HW, Chianini F, Jeffrey M. Factors influencing temporal variation of scrapie incidence within a closed Suffolk sheep flock. J Gen Virol 2012; 93: 203-211
10. Miller MW, Wild MA. Epidemiology of chronic wasting disease in captive white-tailed and mule deer. J Wildl Dis 2004; 40: 320-327
11. Mathiason CK, Hays SA, Powers J, Hayes-Klug J, Langenberg J, Dahmes SJ, Osborn DA, Miller KV, Warren RJ, Mason GL, Hoover EA. Infectious prions in pre-clinical deer and transmission of chronic wasting disease solely by environmental exposure. PLoS ONE 2009; 4: e5916
12. Barron RM, Campbell SL, King D, Bellon A, Chapman KE, Williamson RA, Manson J. High titers of transmissible spongiform encephalopathy infectivity associated with extremely low levels of PrPSc in vivo. J Biol Chem 2007; 282: 35878-35886
13. Caramelli M, Ru G, Casalone C, Bozzetta E, Acutis PL, Calella A, Forloni G. Evidence for the transmission of scrapie to sheep and goats from a vaccine against Mycoplasma agalactiae. Vet Rec 2001; 148: 531-536
14. Prusiner SB. Prion biology and diseases. In Transmissible Subacute Spongiform Encephalopathies: Prion Diseases. Eds L Court, B Dodet . Paris: Elsevier Editions Scientifiques, 1996; 209-237
15. Piccardo P, Manson JC, King D, Ghetti B, Barron RM. Accumulation of prion protein in the brain that is not associated with transmissible disease. Proc Natl Acad Sci U S A 2007; 104: 4712-4717
16. Lasmezas CI, Deslys JP, Robain O, Jaegly A, Beringue V, Peyrin JM, Hauw J, Rossier J, Dormont D. Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science 1997; 275: 402-405
17. Jacobs JG, Sauer M, van Keulen LJ, Tang Y, Bossers A, Langeveld JP. Differentiation of ruminant transmissible spongiform encephalopathy isolate types, including bovine spongiform encephalopathy and CH1641 scrapie. J Gen Virol 2011; 92: 222-232
18. Wickner RB, Edskes HK, Ross ED, Pierce MM, Baxa U, Brachmann A, Shewmaker F. Prion genetics: new rules for a new kind of gene. Annu Rev Genet 2004; 38: 681-707
19. Brown P, Gibbs CJ, Rodgers-Johnston P, Asher D, Sulima MP, Bacote A, Goldfarb LG, Gajdusek DC. Human spongiform encephalopathies: the national institute of health series of 300 cases of experimentally transmitted disease. Ann Neurol 1994; 35: 513-529
20. Ridley RM, Baker HF, Windle CP, Cummings RM. Very long term studies of the seeding of beta-amyloidosis in primates. J Neural Transm 2006; 113: 1243-1251
21. Eisele YS, Obermuller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, Walker LC, Staufenbiel M, Heikenwalder M, Jucker M. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 2010; 330: 980-982
22. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356
23. Small DH, Mok SS, Bornstein JC. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci 2001; 2: 595-598
24. Jellinger KA, Popescu BO. Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med 2012; 16: 1166-1183
25. Tremblay P, Ball HL, Kaneko K, Groth D, Hegde RS, Cohen FE, DeArmond SJ, Prusiner SB, Safar JG. Mutant PrPSc conformers induced by a synthetic peptide and several prion strains. J Virol 2004; 78: 2088-2099
26. Hsiao K, Groth D, Scott M, Yang S-L, Serban H, Rapp D, Foster D, Torchia M, DeArmond SJ, Prusiner SB. Serial transmission in rodents of neurodegeneration from transgenic mice expressing mutant prion protein. Proc Natl Acad Sci U S A 1994; 91: 9126-9130
27. Manson JC, Jamieson E, Baybutt H, Tuzi NL, Barron R, McConnell I, Somerville R, Ironside J, Will R, Sy MS, Melton DW, Hope J, Bostock C. A single amino acid alteration [101L] introduced into murine PrP dramatically alters incubation time of transmissible spongiform encephalopathy. EMBO J 1999; 18: 6855-6864
28. Nazor KE, Kuhn F, Seward T, Green M, Zwald D, Purro M, Schmid J, Biffiger K, Power AM, Oesch B, Raeber AJ, Telling GC. Immunodetection of disease-associated mutant PrP, which accelerates disease in GSS transgenic mice. EMBO J 2005; 24: 2472-2480
29. Kocisko DA, Come JH, Priola SA, Chesebro B, Raymond GJ, Lansbury PT, Caughey B. Cell-free formation of protease-resistant prion protein. Nature 1994; 370: 471-474
30. Walker LC, Callahan MJ, Bian F, Durham RA, Roher AE, Lipinski WJ. Exogenous induction of cerebral beta-amyloidosis in beta APP-transgenic mice. Peptides 2002; 23: 1241-1247
31. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 2000; 20: 4050-4058
32. Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA, Schwarz RD, Roher AE, Walker LC. Evidence for seeding of beta-amyloid by intracerebral infusion of Alzheimer brain extracts in beta-amyloid precursor protein-transgenic mice. J Neurosci 2000; 20: 3606-3611
33. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, Jucker M, Goedert M, Tolnay M. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009; 11: 909-913
34. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003; 39: 409-421
35. Colby DW, Giles K, Legname G, Wille H, Baskakov IV, DeArmond SJ, Prusiner SB. Design and construction of diverse mammalian prion strains. Proc Natl Acad Sci U S A 2009; 106: 20417-20422
36. Deleault NR, Harris BT, Rees JR, Supattapone S. Formation of native prions from minimal components in vitro. Proc Natl Acad Sci U S A 2007; 104: 9741-9746
37. Deleault NR, Kascsak R, Geoghegan JC, Supattapone S. Species-dependent differences in cofactor utilization for formation of the protease-resistant prion protein in vitro. Biochemistry 2010; 49: 3928-3934
38. Wang F, Wang X, Yuan CG, Ma J. Generating a prion with bacterially expressed recombinant prion protein. Science 2010; 327: 1132-1135
39. Wang F, Zhang Z, Wang X, Li J, Zha L, Yuan CG, Weissmann C, Ma J. Genetic informational RNA is not required for recombinant prion infectivity. J Virol 2012; 86: 1874-1876
40. Barria MA, Mukherjee A, Gonzalez-Romero D, Morales R, Soto C. De novo generation of infectious prions in vitro produces a new disease phenotype. PLoS Pathog 2009; 5: e1000421
41. Kim JI, Cali I, Surewicz K, Kong Q, Raymond GJ, Atarashi R, Race B, Qing L, Gambetti P, Caughey B, Surewicz WK. Mammalian prions generated from bacterially expressed prion protein in the absence of any mammalian cofactors. J Biol Chem 2010; 285: 14083-14087
42. Caughey B, Baron GS, Chesebro B, Jeffrey M. Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions. Annu Rev Biochem 2009; 78: 177-204
43. Klingeborn M, Race B, Meade-White KD, Chesebro B. Lower specific infectivity of protease-resistant prion protein generated in cell free reactions. Proc Natl Acad Sci U S A 2011; 108: 1244-1253
44. Miller MB, Geoghegan JC, Supattapone S. Dissociation of infectivity from seeding ability in prions with alternate docking mechanism. PLoS Pathog 2011; 7: e1002128
45. Jackson WS, Borkowski AW, Faas H, Steele AD, King OD, Watson N, Jasanoff A, Lindquist S. Spontaneous generation of prion infectivity in fatal familial insomnia knockin mice. Neuron 2009; 63: 438-450
46. Makarava N, Kovacs GG, Bocharova O, Savtchenko R, Alexeeva I, Budka H, Rohwer RG, Baskakov IV. Recombinant prion protein induces a new transmissible prion disease in wild-type animals. Acta Neuropathol 2010; 119: 177-187
47. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL, Vigouret JM, Paganetti P, Walsh DM, Mathews PM, Ghiso J, Staufenbiel M, Walker LC, Jucker M. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 2006; 313: 1781-1784
48. Balachandran A, Harrington NP, Algire J, Soutyrine A, Spraker TR, Jeffrey M, González L, O'Rourke KI. Experimental oral transmission of chronic wasting disease to red deer [Cervus elaphus elaphus]: early detection and late stage distribution of protease-resistant prion protein. Can Vet J 2010; 51: 169-178
49. González L, Martin S, BegaraMcGorum I, Hunter N, Houston F, Simmons M, Jeffrey M. Effects of agent strain and host genotype on PrP accumulation in the brain of sheep naturally and experimentally affected with scrapie. J Comp Pathol 2002; 126: 17-29
50. Kovacs GG, Head MW, Hegyi I, Bunn TJ, Flicker H, Hainfellner JA, McCardle L, Laszlo L, Jarius C, Ironside JW, Budka H. Immunohistochemistry for the prion protein: comparison of different monoclonal antibodies in human prion disease subtypes. Brain Pathol 2002; 12: 1-11
51. Jeffrey M, McGovern G, Siso S, González L. Cellular and sub-cellular pathology of animal prion diseases: relationship between morphological changes, accumulation of abnormal prion protein and clinical disease. Acta Neuropathol 2011; 121: 113-134
52. Linden R, Cordeiro Y, Lima LM. Allosteric function and dysfunction of the prion protein. Cell Mol Life Sci 2012; 69: 1105-1124
53. Jeffrey M, McGovern G, Goodsir CM, González L. Strain-associated variations in abnormal PrP trafficking of sheep scrapie. Brain Pathol 2009; 19: 1-11
54. Jeffrey M, Martin S, González L. Cell-associated variants of disease-specific prion protein immunolabelling are found in different sources of sheep transmissible spongiform encephalopathy. J Gen Virol 2003; 84: 1033-1046
55. Jeffrey M, McGovern G, Makarava N, González L, Kim J-S, Rohwer RG, Baskakov IV. Pathology of SSLOW, a transmissible and fatal synthetic prion protein disorder and comparison with naturally occurring classical transmissible spongiform encephalopathies. Neuropathol Appl Neurobiol 2013 (in press)
56. Bastian FO. Spiroplasma-like inclusions in Creutzfeldt-Jakob disease. Arch Pathol Lab Med 1979; 103: 665-669
57. Liberski PP, Yanagihara R, Wells GAH, Gajdusek DC. Neuronal degeneration in unconventional slow virus disorders. In Light and Electron Microscopic Neuropathology of Slow Virus Disorders. Ed PP Liberski . Boca Raton, FL: CRC Press, 1993; 349-371
58. Caughey B, Raymond GJ. The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. J Biol Chem 1991; 266: 18217-18223
59. Baron GS, Wehrly K, Dorward DW, Chesebro B, Caughey B. Conversion of raft associated prion protein to the protease-resistant state requires insertion of PrP-res (PrPSc) into contiguous membranes. EMBO J 2002; 21: 1031-1040
60. Ihara Y, Morishima-Kawashima M, Nixon R. The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2: a006361
61. Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, Mohan PS, Mercken M, Farmery MR, Tjernberg LO. Macroautophagy - a novel amyloid-b [Ab] peptide generating pathway activated in Alzheimer's disease. J Cell Biol 2005; 171: 87-98
62. Williams TL, Serpell LC. Membrane and surface interactions of Alzheimer's Abeta peptide-insights into the mechanism of cytotoxicity. FEBS J 2011; 278: 3905-3917
63. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005; 8: 1051-1058
64. Casalone C, Zanusso G, Acutis P, Ferrari S, Capucci L, Tagliavini F. Identification of a second bovine amyloidotic spongiform encephalopathy: molecular similarities with sporadic Creutzfeldt-Jakob disease. Proc Natl Acad Sci U S A 2004; 101: 3065-3070
65. Parchi P, Strammiello R, Notari S, Giese A, Langeveld JP, Ladogana A, Zerr I, Roncaroli F, Cras P, Ghetti B, Pocchiari M, Kretzschmar H, Capellari S. Incidence and spectrum of sporadic Creutzfeldt-Jakob disease variants with mixed phenotype and co-occurrence of PrP[Sc] types: an updated classification. Acta Neuropathol 2009; 118: 659-671
66. Revesz T, Holton JL, Lashley T, Plant G, Frangione B, Rostagno A, Ghiso J. Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathol 2009; 118: 115-130
67. Jeffrey M, Goodsir CM, Bruce ME, McBride PA, Farquhar C. Morphogenesis of amyloid plaques in 87V murine scrapie. Neuropathol Appl Neurobiol 1994; 20: 535-542
68. Liberski PP, Guiroy DC, Williams ES, Yanagihara R, Brown P, Gajdusek DC. The amyloid plaque. In Light and Electron Microscopic Neuropathology of Slow Virus Disorder. Ed PP Liberski . Boca Raton: CRC press, 1993; 295-347
69. Sikorska B, Liberski PP, Sobow T, Budka H, Ironside JW. Ultrastructural study of florid plaques in variant Creutzfeldt-Jakob disease: a comparison with amlyoid plaqes in kuru, Creutzfeldt-Jakob disease and Gerstamnn-Straussler-Scheinker disease. Neuropathol Appl Neurobiol 2009; 35: 46-59
70. Boellaard JW, Schlote W, Heldt N. The development of amyloid plaques in human transmissible encephalopathy and the role of astrocytes in their formation. In Unconventional Virus Diseases of the Central Nervous System. Eds LA Court, D Dormont, P Brown, DT Kingsbury . Paris: Fontenay-aux-Roses, 1989; 162-171
71. Jeffrey M, McGovern G, Chambers EV, King D, Gonzalez L, Manson JC, Ghetti B, Piccardo P, Barron RM. Mechanism of PrP-amyloid formation in mice without transmissible spongiform encephalopathy. Brain Pathol 2012; 22: 58-66
72. Terry RD, Gonatas NK, Weiss M. Ultrastructural studies in Alzheimer's presenile dementia. Am J Pathol 1964; 44: 269-297
73. Liberski PP, Kloszewska I, Boellaard J, Papierz W, Omulecka A, Budka H. Dystrophic neurites of Alzheimer's disease and Gerstmann-Straussler-Scheinker's disease dissociate from the formation of paired helical filaments. Alzheimers Res 1995; 1: 89-93
74. Piccardo P, Cervenak J, Yakovleva O, Gregori L, Pomeroy K, Cook A, Muhammad FS, Seuberlich T, Cervenakova L, Asher DM. Squirrel monkeys (Saimiri sciureus) infected with the agent of bovine spongiform encephalopathy develop tau pathology. J Comp Pathol 2012; 147: 84-93
75. Reiniger L, Lukic A, Linehan J, Rudge P, Collinge J, Mead S, Brandner S. Tau, prions and Abeta: the triad of neurodegeneration. Acta Neuropathol 2011; 121: 5-20
76. Raeber AJ, Race RE, Brandner S, Priola SA, Sailer A, Bessen RA, Mucke L, Manson J, Aguzzi A, Oldstone MBA, Weissmann C, Chesebro B. Astrocyte-specific expression of hamster prion protein [PrP] renders PrP knockout mice susceptible to hamster scrapie. EMBO J 1997; 16: 6057-6065
77. Ilangumaran S, Robinson PJ, Hoessli DC. Transfer of exogenous glycosylphos-phatidylinositol (GPI)-linked molecules to plasma membranes. Trends Cell Biol 1996; 6: 163-167
78. Jeffrey M, Goodsir CM, Race RE, Chesebro B. Scrapie-specific neuronal lesions are independent of neuronal PrP expression. Ann Neurol 2004; 55: 781-792
79. Chesebro B, Trifilo M, Race R, Meade-White K, Teng C, LaCasse R, Raymond L, Favara C, Baron G, Priola S, Caughey B, Masliah E, Oldstone M. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 2005; 308: 1435-1439
80. Chesebro B, Race B, Meade-White K, LaCasse R, Striebel J, Klingeborn M, Race R, McGovern G, Dorward D, Jeffrey M. Fatal transmissible amyloid encephalopathy: a new type of prion disease associated with lack of prion protein membrane anchoring. PLoS Pathog 2010; 6: e1000800
81. Hata S, Saito Y, Suzuki T. Alzheimer's disease as a membrane-associated enzymopathy of beta-amyloid precursor protein (APP) secretases. In Lipids and Cellular Membranes in Amyloid Diseases. Ed R Jelinek . Weinheim: Wiley-VCH Verlag GmbH & Co., 2011; 177-194
82. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 2008; 18: 253-266
83. Bateman DA, Chakrabartty A. Interaction of Alzheimer amyloid peptide with cell surfaces and artificial membranes. In Lipids and Cellular Membranes in Amyloid Diseases. Ed R Jelinek . Weinheim: Wiley-VCH Verlag GmbH & Co., 2011; 231-243
84. Snow AD, Mar H, Nochlin D, Kimata K, Kato M, Suzuki S, Hassell J, Wight TN. The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. Am J Pathol 1988; 133: 456-463
85. Jeffrey M, Halliday WG, Bell J, Johnston AR, MacLeod NK, Ingham C, Sayers AR, Brown DA, Fraser JR. Synapse loss associated with abnormal PrP precedes neuronal degeneration in the scrapie-infected murine hippocampus. Neuropathol Appl Neurobiol 2000; 26: 41-54
86. Gray BC, Siskova Z, Perry VH, O'Connor V. Selective presynaptic degeneration in the synaptopathy associated with ME7-induced hippocampal pathology. Neurobiol Dis 2009; 35: 63-74
87. David-Farreira JF, David-Farreira KL, Gibbs CJ. Scrapie in mice: ultrastructural observations in the cerebral cortex. Proc Soc Exp Biol Med 1968; 127: 313-320
88. Liberski PP, Budka H, Yanagihara R, Gibbs CJ, Gajdusek DC. Tubulovesicular structures. In Light and Electron Microscopic Neuropathology of Slow Virus Disorders. Ed PP Liberski . Boca Raton: CRC Press, 1993; 373-392
89. Simic G, Stanic G, Mladinov M, Jovanov-Milosevic N, Kostovic I, Hof PR. Does Alzheimer's disease begin in the brainstem? Neuropathol Appl Neurobiol 2009; 35: 532-554
90. Carare RO, Bernardes-Silva M, Newman TA, Page AM, Nicoll JAR, Perry VH, Weller RO. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol Appl Neurobiol 2012; 34: 131-144
91. Szentistvanyi I, Patlak CS, Ellis RA, Cserr HF. Drainage of interstitial fluid from different regions of rat brain. Am J Physiol 1984; 246: 834-844
92. Weller RO, Djuanda E, Yow HY, Carare RO. Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol 2009; 117: 1-14
93. Weller RO, Galea I, Carare RO, Minagar A. Pathophysiology of the lymphatic drainage of the central nervous system: implications for pathogenesis and therapy of multiple sclerosis. Pathophysiology 2010; 17: 295-306
94. Schroder R, Linke RP. Cerebrovascular involvement in systemic AA and AL amyloidosis: a clear haematogenic pattern. Virchows Arch 1999; 434: 551-560
95. Siso S, Jeffrey M, González L. Neuroinvasion in sheep transmissible spongiform encephalopathies: the role of the haematogenous route. Neuropathol Appl Neurobiol 2009; 35: 232-246
96. Siso S, Jeffrey M, Martin S, Houston F, Hunter N, González L. Pathogenetical significance of porencephalic lesions associated with intracerebral inoculation of sheep with the bovine spongiform encephalopathy (BSE) agent. Neuropathol Appl Neurobiol 2009; 35: 247-258
97. Yamaguchi H, Yamazaki T, Lemere CA, Frosch MP, Selkoe DJ. Beta amyloid is focally deposited within the outer basement membrane in the amyloid angiopathy of Alzheimer's disease. An immunoelectron microscopic study. Am J Pathol 1992; 141: 249-259
98. Dietrich HH, Xiang C, Han BH, Zipfel GJ, Holtzman DM. Soluble amyloid-beta, effect on cerebral arteriolar regulation and vascular cells. Mol Neurodegener 2010; 5: 15-21
99. Barron RM, Baybutt H, Tuzi NL, McCormack J, King D, Moore RC, Melton DW, Manson JC. Polymorphisms at codons 108 and 189 in murine PrP play distinct roles in the control of scrapie incubation time. J Gen Virol 2005; 86: 859-868
100. Makarava N, Kovacs GG, Savtchenko R, Alexeeva I, Ostapchenko VG, Budka H, Rohwer RG, Baskakov IV. A new mechanism for transmissible prion diseases. J Neurosci 2012; 32: 7345-7355
101. Makarava N, Kovacs GG, Savtchenko R, Alexeeva I, Budka H, Rohwer RG, Baskakov IV. Genesis of mammalian prions: from non-infectious amyloid fibrils to a transmissible prion disease. PLoS Pathog 2011; 7: e1002419
102. Watts JC, Giles K, Grillo SK, Lemus A, DeArmond SJ, Prusiner SB. Bioluminescence imaging of Abeta deposition in biogenic mouse models of Alzheimer's disease. Proc Natl Acad Sci U S A 2011; 108: 2528-2533
103. Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 2010; 11: 301-307
104. Jeffrey M, González L, Espenes A, Press C, Martin S, Chaplin M, Davis L, Landsverk T, Macaldowie C, Eaton S, McGovern G. Transportation of prion protein across the intestinal mucosa of scrapie-susceptible and scrapie-resistant sheep. J Pathol 2006; 209: 4-14